Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Trinity Biotech (TRIB) over the last 17 years, with Q2 2025 value amounting to $28000.0.

  • Trinity Biotech's Other Non-Current Assets fell 6455.7% to $28000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $28000.0, marking a year-over-year decrease of 6455.7%. This contributed to the annual value of $28000.0 for FY2024, which is 6455.7% down from last year.
  • Latest data reveals that Trinity Biotech reported Other Non-Current Assets of $28000.0 as of Q2 2025, which was down 6455.7% from $28000.0 recorded in Q4 2024.
  • Over the past 5 years, Trinity Biotech's Other Non-Current Assets peaked at $315000.0 during Q1 2021, and registered a low of $28000.0 during Q4 2024.
  • For the 5-year period, Trinity Biotech's Other Non-Current Assets averaged around $140176.5, with its median value being $120000.0 (2023).
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first tumbled by 2580.65% in 2022, then crashed by 6455.7% in 2024.
  • Over the past 5 years, Trinity Biotech's Other Non-Current Assets (Quarter) stood at $207000.0 in 2021, then tumbled by 32.85% to $139000.0 in 2022, then plummeted by 43.17% to $79000.0 in 2023, then tumbled by 64.56% to $28000.0 in 2024, then changed by 0.0% to $28000.0 in 2025.
  • Its Other Non-Current Assets stands at $28000.0 for Q2 2025, versus $28000.0 for Q4 2024 and $43000.0 for Q3 2024.